Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?

Key Points

• SGIOY shares moved above their 200-day moving average, reaching $9.85 before last trading at $9.635, compared with a 200-day average of $9.63.
• Analyst sentiment strengthened as Jefferies and Zacks Research upgraded the ADR to “strong buy”; all three covered analysts now rate it Strong Buy.
• Shionogi exceeded quarterly expectations, reporting $0.36 EPS versus the $0.18 consensus and $1.04 billion in revenue versus estimates of $970.69 million.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.63 and traded as high as $9.85. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.6350, with a volume of 52,024 shares traded.

Analyst Upgrades and Downgrades

SGIOY has been the topic of a number of recent analyst reports. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 14th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the company currently has an average rating of "Strong Buy".

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 0.3%

The stock has a market cap of $16.40 billion, a PE ratio of 9.63, a price-to-earnings-growth ratio of 3.45 and a beta of 0.08. The company has a 50 day moving average of $9.12 and a two-hundred day moving average of $9.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. Sell-side analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.